Literature DB >> 26585387

NADP(+)-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance.

Feng Li1, Xiadi He2, Dingwei Ye3, Yan Lin1, Hongxiu Yu4, Cuifang Yao5, Lei Huang6, Jianong Zhang6, Fang Wang4, Sha Xu5, Xiaohui Wu7, Lixia Liu8, Chen Yang8, Jiaqi Shi9, Xiaoyang He10, Jie Liu11, Yuanyuan Qu3, Fushen Guo12, Jianyuan Zhao6, Wei Xu13, Shimin Zhao14.   

Abstract

Elucidating the tumorigenic mechanism of R-2-hydroxyglutarate (R-2HG) is critical for determining how NADP(+)-IDH mutations cause cancer. Here we report that R-2HG induces cancerous metabolism and apoptosis resistance through promoting hypersuccinylation. By competitive inhibition of the mitochondrial tricarboxylic acid cycle enzyme succinate dehydrogenase (SDH), R-2HG preferentially induced succinyl-CoA accumulation and hypersuccinylation in the mitochondria. IDH1 mutation-bearing glioma samples and cells were hypersuccinylated in the mitochondria. IDH1 mutation or SDH inactivation resulted in hypersuccinylation, causing respiration inhibition and inducing cancerous metabolism and mitochondrial depolarization. These mitochondrial dysfunctions induced BCL-2 accumulation at the mitochondrial membrane, leading to apoptosis resistance of hypersuccinylated cells. Relief of hypersuccinylation by overexpressing the desuccinylase SIRT5 or supplementing glycine rescued mitochondrial dysfunctions, reversed BCL-2 accumulation, and slowed the oncogenic growth of hypersuccinylated IDH1(R132C)-harboring HT1080 cells. Thus, R-2HG-induced hypersuccinylation contributes to the tumorigenicity of NADP(+)-IDH mutations, suggesting the potential of hypersuccinylation inhibition as an intervention for hypersuccinylation-related tumors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26585387     DOI: 10.1016/j.molcel.2015.10.017

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   19.328


  66 in total

1.  Discovery of a novel calcium-sensitive fluorescent probe for α-ketoglutarate.

Authors:  Lin-Lin Gan; Lin-Hai Chen; Fa-Jun Nan
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

Review 2.  Overcoming therapeutic resistance in glioblastoma: the way forward.

Authors:  Satoru Osuka; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

3.  Emerging Roles for SIRT5 in Metabolism and Cancer.

Authors:  Lauren R Bringman-Rodenbarger; Angela H Guo; Costas A Lyssiotis; David B Lombard
Journal:  Antioxid Redox Signal       Date:  2017-10-26       Impact factor: 8.401

Review 4.  Mitochondrial Complex II: At the Crossroads.

Authors:  Ayenachew Bezawork-Geleta; Jakub Rohlena; Lanfeng Dong; Karel Pacak; Jiri Neuzil
Journal:  Trends Biochem Sci       Date:  2017-02-07       Impact factor: 13.807

Review 5.  To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.

Authors:  Bharathan Bhavya; C R Anand; U K Madhusoodanan; P Rajalakshmi; K Krishnakumar; H V Easwer; A N Deepti; Srinivas Gopala
Journal:  Cell Mol Neurobiol       Date:  2019-09-04       Impact factor: 5.046

Review 6.  The dawn of succinylation: a posttranslational modification.

Authors:  Matthew Alleyn; Mason Breitzig; Richard Lockey; Narasaiah Kolliputi
Journal:  Am J Physiol Cell Physiol       Date:  2017-11-22       Impact factor: 4.249

Review 7.  Oncometabolites in renal cancer.

Authors:  Cissy Yong; Grant D Stewart; Christian Frezza
Journal:  Nat Rev Nephrol       Date:  2019-10-21       Impact factor: 28.314

8.  SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer.

Authors:  Xiu-Fei Chen; Meng-Xin Tian; Ren-Qiang Sun; Meng-Li Zhang; Li-Sha Zhou; Lei Jin; Lei-Lei Chen; Wen-Jie Zhou; Kun-Long Duan; Yu-Jia Chen; Chao Gao; Zhou-Li Cheng; Fang Wang; Jin-Ye Zhang; Yi-Ping Sun; Hong-Xiu Yu; Yu-Zheng Zhao; Yi Yang; Wei-Ren Liu; Ying-Hong Shi; Yue Xiong; Kun-Liang Guan; Dan Ye
Journal:  EMBO Rep       Date:  2018-02-28       Impact factor: 8.807

9.  Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.

Authors:  Lucille Stuani; Marie Sabatier; Estelle Saland; Guillaume Cognet; Nathalie Poupin; Claudie Bosc; Florence A Castelli; Lara Gales; Evgenia Turtoi; Camille Montersino; Thomas Farge; Emeline Boet; Nicolas Broin; Clément Larrue; Natalia Baran; Madi Y Cissé; Marc Conti; Sylvain Loric; Tony Kaoma; Alexis Hucteau; Aliki Zavoriti; Ambrine Sahal; Pierre-Luc Mouchel; Mathilde Gotanègre; Cédric Cassan; Laurent Fernando; Feng Wang; Mohsen Hosseini; Emeline Chu-Van; Laurent Le Cam; Martin Carroll; Mary A Selak; Norbert Vey; Rémy Castellano; François Fenaille; Andrei Turtoi; Guillaume Cazals; Pierre Bories; Yves Gibon; Brandon Nicolay; Sébastien Ronseaux; Joseph R Marszalek; Koichi Takahashi; Courtney D DiNardo; Marina Konopleva; Véra Pancaldi; Yves Collette; Floriant Bellvert; Fabien Jourdan; Laetitia K Linares; Christian Récher; Jean-Charles Portais; Jean-Emmanuel Sarry
Journal:  J Exp Med       Date:  2021-05-03       Impact factor: 14.307

Review 10.  Chemical and Physiological Features of Mitochondrial Acylation.

Authors:  Alison E Ringel; Sarah A Tucker; Marcia C Haigis
Journal:  Mol Cell       Date:  2018-11-15       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.